## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1 - 10. (canceled).

11. (new) A pharmaceutical composition comprising at least one compound of formula (C) or (D) and a pharmaceutically acceptable carrier which is useful in a medicine

wherein -X' is

m is 0 or 1;

Y' is

Q is CH or N;

 $R^6$  is  $CO_2H$ ,  $CO_2Alkyl$ ,  $CO_2Aryl$ ,  $CO_2NH_2$ ,  $CO_2Aralkyl$ ,  $SO_3H$ ,  $SO_2NH_2$ ,  $PO(OH)_2$ , 1-H-tetrazolyl, CHO, COCH<sub>3</sub>,  $CH_2OH$ ,  $NH_2$ , NHAlkyl, N(Alkyl)Alkyl,  $OCH_3$ ,  $CH_2OCH_3$ , SH, F, Cl, Br, I,  $CH_3$ ,  $CH_2CH_3$ , CN, or  $CF_3$ ;

R<sup>7</sup>, independently from R<sup>6</sup>, is H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CF<sub>3</sub>, F, Cl, Br, I, CN, or NO<sub>2</sub>;

 $R^8$ , independently from  $R^6$  and  $R^7$ , is H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CF<sub>3</sub>, F, CI, Br, I, CN, NO<sub>2</sub>, or  $R^6$ ;

R<sup>9a</sup> is H, NO<sub>2</sub>, CF<sub>3</sub>, F, Cl, Br, I, CN, CH<sub>3</sub>, OCH<sub>3</sub>, SH, or NH<sub>2</sub>;

 $R^{9b}$ , independently from  $R^{9a}$ , is H, NO<sub>2</sub>, CF<sub>3</sub>, F, CI, Br, I, CN, CH<sub>3</sub>, OCH<sub>3</sub>, SH, or NH<sub>2</sub>;

Serial No. 10/593,259 Attorney Docket No. 1043.0005-00000

R<sup>10</sup> is CO<sub>2</sub>H, CO<sub>2</sub>alkyl, CO<sub>2</sub>aryl, CO<sub>2</sub>NH<sub>2</sub>, CO<sub>2</sub>aralkyl, CH<sub>2</sub>SO<sub>3</sub>H, CH<sub>2</sub>SO<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>PO(OH)<sub>2</sub>, 1-H-tetrazolyl, CHO, COCH<sub>3</sub>, CH<sub>2</sub>OH, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NHalkyl, CH<sub>2</sub>N(alkyl)alkyl', CH<sub>2</sub>OCH<sub>3</sub>, or CH<sub>2</sub>SH; R<sup>11</sup> is CO<sub>2</sub>H, CO<sub>2</sub>alkyl, CO<sub>2</sub>aryl, CO<sub>2</sub>NH<sub>2</sub>, CO<sub>2</sub>aralkyl, SO<sub>3</sub>H, SO<sub>2</sub>NH<sub>2</sub>, PO(OH)<sub>2</sub>, 1-H-tetrazolyl, CHO, COCH<sub>3</sub>, OH, NH<sub>2</sub>, NHalkyl, N(alkyl)alkyl', OCH<sub>3</sub>, or SH; s is 1; t is 0, 1, or 2; -W- is -(CH<sub>2</sub>-)<sub>v</sub>, *cis*-CH=CH- or *trans*-CH=CH-, and v is 0,1,or 2; in case that R<sup>6</sup> is NH<sub>2</sub>, R<sup>7</sup> or R<sup>8</sup> or R<sup>9a</sup> must not be H; and in case that -W- is *cis*-CH=CH- or *trans*-CH=CH-, R<sup>6</sup> must not be NH<sub>2</sub> or SH; or the pharmaceutically acceptable salts, esters, or amides of the compounds of formula (C) or (D).

- 12. (new) A pharmaceutical composition of claim 11 wherein the at least one compound is a compound of formula (C).
- 13. (new) A pharmaceutical composition of claim 11 wherein the at least one compound is a compound of formula (D).
- 14. (new) Use of compounds having the structure of formula (C) or (D) as defined in claim 1 for the preparation of a medicine for the treatment of a patient, inhibiting the binding of P-selectin, L-selectin or E-selectin to sLe<sup>x</sup> or sLe<sup>a</sup> and tyrosinesulfate residues.
- 15. (new) Use of compounds having the structure of formula (C) or (D) as defined in claim 1 for the preparation of a medicine for the treatment, diagnosis, or prophylaxis of inflammatory disorders.
- 16. (new) Use of compounds having the structure of formula (C) or (D) as defined in claim 1 for the preparation of a medicine for the treatment of Chronic Obstructive Pulmonary Disease (COPD), acute respiratory distress syndrome (ARDS), Crohn's disease, septic shock, sepsis, chronic inflammatory diseases, psoriasis, atopic dermatitis, rheumatoid arthritis, reperfusion injury that occurs following heart attacks, strokes, atherosclerosis, organ transplants, traumatic shock, multi-organ failure, or an autoimmune disease selected from multiple sclerosis, asthma, and inflammatory bowel disease.